Academic Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge CB2 9NB, UK.
MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK.
Science. 2022 Apr 22;376(6591). doi: 10.1126/science.abl9283.
Whole-genome sequencing (WGS) permits comprehensive cancer genome analyses, revealing mutational signatures, imprints of DNA damage and repair processes that have arisen in each patient's cancer. We performed mutational signature analyses on 12,222 WGS tumor-normal matched pairs, from patients recruited via the UK National Health Service. We contrasted our results to two independent cancer WGS datasets, the International Cancer Genome Consortium (ICGC) and Hartwig Foundation, involving 18,640 WGS cancers in total. Our analyses add 40 single and 18 double substitution signatures to the current mutational signature tally. Critically, we show for each organ, that cancers have a limited number of 'common' signatures and a long tail of 'rare' signatures. We provide a practical solution for utilizing this concept of common versus rare signatures in future analyses.
全基因组测序(WGS)允许全面的癌症基因组分析,揭示突变特征,DNA 损伤和修复过程的痕迹,这些特征在每个患者的癌症中都出现过。我们对通过英国国家卫生服务系统招募的 12222 对 WGS 肿瘤-正常匹配对进行了突变特征分析。我们将我们的结果与两个独立的癌症 WGS 数据集,即国际癌症基因组联盟(ICGC)和哈特威格基金会(Hartwig Foundation)进行了对比,总共涉及 18640 个 WGS 癌症。我们的分析为当前的突变特征总数增加了 40 个单取代特征和 18 个双取代特征。至关重要的是,我们为每个器官表明,癌症有有限数量的“常见”特征和大量的“罕见”特征。我们为在未来的分析中利用常见特征和罕见特征的概念提供了一个实用的解决方案。